Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.67 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419394 | 0.90 | EGLN3 (0.66) | EGLN3EGLN1EGLN2MEN1KMT2A | |
| SCHEMBL3420439 | 0.88 | EGLN3 (0.64) | EGLN3EGLN1MEN1KMT2AKDM4E | |
| SCHEMBL3421192 | 0.87 | EGLN3 (0.69) | EGLN3EGLN1EGLN2KDM4ELMNA | |
| SCHEMBL15422839 | 0.86 | EGLN3 (0.57) | EGLN3EGLN1HDAC6HDAC1HDAC8 | |
| SCHEMBL3419511 | 0.86 | EGLN3 (0.62) | EGLN3EGLN1MEN1KMT2AKDM4E | |
| SCHEMBL3422298 | 0.86 | EGLN3 (0.64) | EGLN3EGLN1EGLN2LMNA | |
| SCHEMBL14790974 | 0.85 | EGLN3 (0.69) | EGLN3EGLN1EGLN2 | |
| SCHEMBL3419559 | 0.83 | EGLN3 (0.67) | EGLN3EGLN1EGLN2 | |
| SCHEMBL3422070 | 0.82 | EGLN3 (0.62) | EGLN3EGLN1EGLN2 | |
| SCHEMBL3420498 | 0.82 | EGLN3 (0.66) | EGLN3EGLN1HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | claimed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | claimed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | claimed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | claimed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | claimed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3472/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3472/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3472/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3409/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3472/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HDAC6 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.